Loading…
Based on limited metadata, this FDA Warning Letter issued to Zhejiang Huahai Pharmaceutical on November 29, 2018, concerns drug manufacturing or product quality issues. Without access to the full letter text or specific subject line details, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. Additional documentation would be needed to identify the particular compliance concerns or affected drug products.